Ligand Pharmaceuticals INC Form 4 insider transactions

Ligand Pharmaceuticals Director John W. Kozarich sold 467 shares of common stock on March 2, 2026, under a pre-arranged 10b5-1 trading plan.

A director of Ligand Pharmaceuticals Inc. sold 467 shares of common stock on February 2, 2026, under a pre-arranged 10b5-1 trading plan.

Ligand Pharmaceuticals Director John W. Kozarich reported the sale of 467 shares of common stock on January 2, 2026, executed under a pre-arranged 10b5-1 trading plan.

Ligand Pharmaceuticals CFO Octavio Espinoza acquired 8 shares of common stock through the company's Employee Stock Purchase Plan at $95.676 per share.

Pelthos Therapeutics shareholders approved a waiver, leading to a reduced conversion price for Ligand Pharmaceuticals' senior secured convertible note.

Ligand Pharmaceuticals Inc.'s Chief Financial Officer, Octavio Espinoza, acquired 2,381 shares of common stock through the exercise of employee stock options on December 16, 2025.

LIGAND PHARMACEUTICALS' Chief Financial Officer, Octavio Espinoza, reported the sale of 1,804 shares of common stock for $188.31 per share.

Ligand Pharmaceuticals CFO Octavio Espinoza disposed of 1,862 shares of common stock to cover tax liabilities related to restricted stock unit settlement.

Ligand Pharmaceuticals director Jason Aryeh exercised non-qualified stock options to acquire 2,034 shares of common stock at $69.51 per share.

Ligand Pharmaceuticals CEO Todd C. Davis reported a gift of 130 common shares to a charitable entity.

LIGAND PHARMACEUTICALS Director John W. Kozarich sold 467 shares of common stock on December 1, 2025, through a pre-arranged 10b5-1 trading plan.

Ligand Pharmaceuticals Director Nancy Ryan Gray exercised stock options and immediately sold the acquired shares, maintaining her beneficial ownership at 8,094 shares.

Ligand Pharmaceuticals director John L. LaMattina exercised stock options and sold a total of 4,179 common shares on November 7, 2025.

Ligand Pharmaceuticals Inc. acquired a $9 million senior secured convertible note in Pelthos Therapeutics Inc., convertible into common stock at $34.442 per share.

LIGAND PHARMACEUTICALS INC Director John W. Kozarich sold 467 shares of common stock on November 3, 2025, through a pre-arranged 10b5-1 trading plan.

Ligand Pharmaceuticals Director John W. Kozarich sold 467 shares of common stock on October 1, 2025, under a pre-arranged 10b5-1 trading plan.

Ligand Pharmaceuticals Director Jason Aryeh sold 9,900 shares of common stock for approximately $1.7 million on September 23, 2025.

Ligand Pharmaceuticals director Martine Zimmermann had 115 shares withheld for tax purposes related to restricted stock units.

A director at Ligand Pharmaceuticals Inc. sold 467 shares of common stock on September 2, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Ligand Pharmaceuticals' CLO and Secretary, Andrew Reardon, reported a disposition of 1,325 common shares for tax purposes.

A director at Ligand Pharmaceuticals Inc. sold 467 shares of common stock for approximately $131.88 per share under a pre-arranged trading plan.

Ligand Pharmaceuticals Inc. Director John W. Kozarich sold 934 shares of common stock for $125 per share on July 10, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Ligand Pharmaceuticals Inc. has significantly increased its beneficial ownership in Pelthos Therapeutics Inc. through the acquisition of common stock and convertible preferred stock following a strategic merger and a 1-for-10 reverse stock split.

Ligand Pharmaceuticals' Chief Legal Officer and Secretary, Andrew Reardon, acquired 233 shares of common stock at $91.0775 per share through the company's Employee Stock Purchase Plan.

Ligand Pharmaceuticals Inc.'s Chief Financial Officer, Octavio Espinoza, acquired 224 shares of common stock at $91.0775 per share through the company's Employee Stock Purchase Plan.

Todd C. Davis, CEO and Director of Ligand Pharmaceuticals Inc., acquired 233 shares of common stock through an employee stock purchase plan.

Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals Inc., reported the sale of 500 shares of common stock as part of a Rule 10b5-1 trading plan.

Ligand Pharmaceuticals' Chief Legal Officer and Secretary, Andrew Reardon, reported the sale of 500 shares of common stock for approximately $114.54 per share, reducing his direct beneficial ownership to 32,403 shares.

Ligand Pharmaceuticals Inc. Director Nancy Ryan Gray was granted 1,209 restricted stock units and 5,783 non-qualified stock options as part of her compensation, according to a recent SEC Form 4 filing.

Ligand Pharmaceuticals Inc. Director and 10% owner Jason Aryeh reported the acquisition of 1,209 restricted stock units and 5,783 non-qualified stock options as part of a Board grant on June 6, 2025.